Tandem Diabetes

Forecast & Rating24 analysts currently cover Tandem Diabetes, with about 58.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $28.35, about 71.8% upside from the current price of $16.50. Price targets range from $18.00 to $50.00 — a wide spread, showing clear disagreement over just how much Tandem Diabetes can rise. Historically, about 49.1% of past price targets were eventually met, which adds credibility. For you, this means institutional views on Tandem Diabetes are split — bulls and bears coexist, so you'll need to weigh it against your own judgment. Data as of Oct 1, 2026; for reference only and not investment advice.